- Home
- NTRB vs ICCM Comparison
NTRB vs ICCM Comparison
Compare NTRB & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- ICCM
- Stock Information
- Founded
- NTRB 2016
- ICCM 2006
- Country
- NTRB United States
- ICCM Israel
- Employees
- NTRB N/A
- ICCM N/A
- Industry
- NTRB Industrial Specialties
- ICCM
- Sector
- NTRB Health Care
- ICCM
- Exchange
- NTRB Nasdaq
- ICCM Nasdaq
- Market Cap
- NTRB 59.1M
- ICCM 59.9M
- IPO Year
- NTRB N/A
- ICCM N/A
- Fundamental
- Price
- NTRB $9.99
- ICCM $1.07
- Analyst Decision
- NTRB Buy
- ICCM Strong Buy
- Analyst Count
- NTRB 1
- ICCM 1
- Target Price
- NTRB $13.00
- ICCM $2.50
- AVG Volume (30 Days)
- NTRB 128.8K
- ICCM 321.2K
- Earning Date
- NTRB 09-02-2025
- ICCM 08-19-2025
- Dividend Yield
- NTRB N/A
- ICCM N/A
- EPS Growth
- NTRB N/A
- ICCM N/A
- EPS
- NTRB N/A
- ICCM N/A
- Revenue
- NTRB $2,398,437.00
- ICCM $3,273,000.00
- Revenue This Year
- NTRB $560.75
- ICCM $83.41
- Revenue Next Year
- NTRB $588.39
- ICCM $185.02
- P/E Ratio
- NTRB N/A
- ICCM N/A
- Revenue Growth
- NTRB 18.92
- ICCM 0.34
- 52 Week Low
- NTRB $3.72
- ICCM $0.48
- 52 Week High
- NTRB $11.78
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- NTRB 69.95
- ICCM 56.78
- Support Level
- NTRB $7.52
- ICCM $0.96
- Resistance Level
- NTRB $11.68
- ICCM $1.03
- Average True Range (ATR)
- NTRB 0.67
- ICCM 0.07
- MACD
- NTRB 0.19
- ICCM 0.01
- Stochastic Oscillator
- NTRB 62.19
- ICCM 87.81
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.